Redwood City, CA - Pathwork Diagnostics, Inc., a pioneer in creating genomics-based diagnostics in oncology utilizing their proprietary informatics platform, today announced the hiring of Sharon Tetlow as chief financial officer.
"We are delighted to welcome Ms. Tetlow to the Pathwork team," said Deborah Neff, chief executive officer of Pathwork. "Sharon's considerable experience as CFO in both public and private companies will be invaluable as we execute our strategy to create and commercialize high value molecular diagnostics to help guide cancer treatment."
"I am thrilled to join Pathwork's outstanding management team during this exciting time in the company's history," said Ms. Tetlow. "Pathwork's proprietary informatics platform has proven itself with the Pathwork® Tissue of Origin Test, and has enormous further potential. I look forward to contributing to the company's next stage of growth."
Ad Statistics
Times Displayed: 51285
Times Visited: 1490 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
Ms. Tetlow has over a dozen years of experience as CFO in life sciences and a strong track record of strategic execution and capital raising. She was most recently senior vice president and CFO of Cell Genesys, a publicly traded biotechnology company which she was instrumental in selling to BioSante (BPAX). She served as a venture partner at Apax Partners, a private equity and venture firm, and previously served as senior vice president and chief financial officer of diaDexus, where she raised private capital to fund the development and successful launch of the company's first product.
She also served as CFO of Reprogen and Terrapin, both private biotechnology companies. Prior to Terrapin, Ms. Tetlow worked in finance at Synergen, Genentech and Eli Lilly. Ms. Tetlow began her career in Washington D.C. where she worked in consulting at Lewin and Associates and then at the Brookings Institution. She holds a BA from the University of Delaware and an MBA from Stanford University.
About the Pathwork Tissue of Origin Test
The company's Pathwork Tissue of Origin Test is the only FDA-cleared, Medicare-covered molecular diagnostic test for tissue of origin. It uses a tumor's own genomic information to help pathologists and oncologists in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history.
The Pathwork Tissue of Origin Test, available through the Pathwork Diagnostics Laboratory, measures gene expression levels of 2,000 genes and uses proprietary algorithms to compare the tumor's gene expression pattern to that of 15 tumor types, representing 58 morphologies and 90% of all solid tumors. The test provides objective genomic information to help the physician diagnose what type of cancer the patient has. Diagnosis allows oncologists to match therapy to the cancer.
